Biological drugs are complex molecules made in living cells, and they have changed medicine in the past two decades, offering rich choices for companies making almost identical copies as patents expire.
New start-up companies are constantly commercialising new technologies and services. Genomics is ripe for investment right now.
The Food and Drug Administration (FDA) has been busy this week. Their most recent approval is for Johnson & Johnson’s Erleada for use in prostate cancer patients whose disease has not spread but continues to grow despite hormone therapy.
Britain’s Oxford BioMedica has a lot to be happy about right now, since its win in a second $100 million contract to supply gene therapy material from Bioverativ.
With Brexit discussions still ongoing, GlaxoSmithKline’s chief executive, Emma Walmsley is taking no chances as she urges the government to sign a two-year transition deal by April to ensure the industry can cope.
Gilead Sciences has moved closer to capturing more of the multibillion-dollar HIV drug market, with its recent drug approval from the U.S. Food and Drug Administration.
Pfizer has announced a two-year collaboration with DL Medicine, intended to produce new chemical entities against preselected targets from multiple therapeutic areas.
European drugmaker and the world’s biggest insulin maker, Novo Nordisk, wants to prove it can transform the diabetes market with a pill.
If you aren’t aware of PubMed Commons, it is a tool that allows scientists to comment on articles indexed in the agency’s popular PubMed database of biomedical literature. Well, after five years its closed its doors.
UK’s biggest drugmaker, GlaxoSmithKline is poised to post record sales of over £30 billion for the first time, in Chief Executive Emma Walmsley’s first set of full-year results this week.
Skyhawk Therapeutics, focused on the discovery and development of small molecule therapeutics that correct RNA expression, has announced the close of $8 million in seed funding led by major family and biotech investors.